Cargando…

Comparing one dose of HPV vaccine in girls aged 9–14 years in Tanzania (DoRIS) with one dose of HPV vaccine in historical cohorts: an immunobridging analysis of a randomised controlled trial

BACKGROUND: Human papillomavirus (HPV) vaccines are given as a two-dose schedule in children aged 9–14 years, or as three doses in older individuals. We compared antibody responses after one dose of HPV vaccine in the Dose Reduction Immunobridging and Safety Study (DoRIS), a randomised trial of diff...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baisley, Kathy, Kemp, Troy J, Kreimer, Aimée R, Basu, Partha, Changalucha, John, Hildesheim, Allan, Porras, Carolina, Whitworth, Hilary, Herrero, Rolando, Lacey, Charles J, Schiller, John T, Lucas, Eric, Mutani, Paul, Dillner, Joakim, Indangasi, Jackton, Muwonge, Richard, Hayes, Richard J, Pinto, Ligia A, Watson-Jones, Deborah
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9638025/ https://www.ncbi.nlm.nih.gov/pubmed/36113532 http://dx.doi.org/10.1016/S2214-109X(22)00306-0

Ejemplares similares

A dose-reduction HPV vaccine immunobridging trial of two HPV vaccines among adolescent girls in Tanzania (the DoRIS trial) – Study protocol for a randomised controlled trial
por: Baisley, Kathy J., et al.
Publicado: (2021)

Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial
por: Watson-Jones, Deborah, et al.
Publicado: (2022)

An update on one-dose HPV vaccine studies, immunobridging and humoral immune responses – A meeting report
por: Waheed, Dur-e-Nayab, et al.
Publicado: (2023)

Does the number of doses matter? A qualitative study of HPV vaccination acceptability nested in a dose reduction trial in Tanzania
por: Mitchell, K.R., et al.
Publicado: (2021)

Evidence for single-dose protection by the bivalent HPV vaccine—Review of the Costa Rica HPV vaccine trial and future research studies
por: Kreimer, Aimée R., et al.
Publicado: (2018)

HPV vaccine: One, two, or three doses for cervical cancer prevention?
por: Mishra, Gauravi A., et al.
Publicado: (2015)

The one-dose schedule opens the door to rapid scale-up of HPV vaccination
por: Zou, Zhuoru, et al.
Publicado: (2023)

Costs of delivering human papillomavirus vaccination using a one- or two-dose strategy in Tanzania
por: Hsiao, Amber, et al.
Publicado: (2023)

Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study
por: Sankaranarayanan, Rengaswamy, et al.
Publicado: (2016)

Effective HPV vaccination coverage in Australia by number of doses and two-dose spacing: What if one or two doses are sufficient?
por: Smith, Megan A., et al.
Publicado: (2021)

Proof-of-Principle Evaluation of the Efficacy of Fewer Than Three Doses of a Bivalent HPV16/18 Vaccine
por: Kreimer, Aimée R., et al.
Publicado: (2011)

One-dose Human Papillomavirus (HPV) vaccine offers solid protection against cervical cancer
Publicado: (2022)

Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development
por: Pinto, Ligia A., et al.
Publicado: (2018)

Impact of HPV vaccination on HPV-related oral infections
por: Gheit, Tarik, et al.
Publicado: (2023)

Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study
por: Basu, Partha, et al.
Publicado: (2021)

HPV16 infection decreases vaccine-induced HPV16 antibody avidity: the CVT trial
por: Tsang, Sabrina H., et al.
Publicado: (2022)

Evaluation of immune response to single dose of quadrivalent HPV vaccine at 10-year post-vaccination
por: Joshi, Smita, et al.
Publicado: (2023)

Analysis of cervical HPV infections among unvaccinated young adult women to inform vaccine strategies in this age group: the Costa Rica HPV Vaccine Trial
por: Sierra, Mónica S., et al.
Publicado: (2023)

Single-dose nonavalent HPV vaccine: Need of the hour
por: Pal, Manidip, et al.
Publicado: (2020)

Reasons for Receiving or Not Receiving HPV Vaccination in Primary Schoolgirls in Tanzania: A Case Control Study
por: Watson-Jones, Deborah, et al.
Publicado: (2012)

Selective Persistence of HPV Cross-Neutralising Antibodies following Reduced-Dose HPV Vaccine Schedules
por: Toh, Zheng Quan, et al.
Publicado: (2019)

Impact of one and two human papillomavirus (HPV) vaccine doses on community-level HPV prevalence in South African adolescent girls: study protocol and rationale for a pragmatic before–after design
por: Machalek, Dorothy, et al.
Publicado: (2022)

Reduced Prevalence of Oral Human Papillomavirus (HPV) 4 Years after Bivalent HPV Vaccination in a Randomized Clinical Trial in Costa Rica
por: Herrero, Rolando, et al.
Publicado: (2013)

HPV vaccination bridges to HPV screening
por: Harper, Diane M, et al.
Publicado: (2020)

Special Issue: HPV and HPV Vaccines
por: Hibma, Merilyn
Publicado: (2022)

SINGLE HPV VACCINE DOSE MAY BE EFFECTIVE AGAINST CERVICAL CANCER
Publicado: (2020)

A Scalable Manufacturing Approach to Single Dose Vaccination against HPV
por: Shao, Shuai, et al.
Publicado: (2021)

Efficacy of single-dose HPV vaccination among young African women
por: Barnabas, Ruanne V., et al.
Publicado: (2022)

Association of provider HPV vaccination training with provider assessment of HPV vaccination status and recommendation of HPV vaccination
por: Osaghae, Ikponmwosa, et al.
Publicado: (2022)

Effect of bivalent human papillomavirus vaccination on pregnancy outcomes: long term observational follow-up in the Costa Rica HPV Vaccine Trial
por: Panagiotou, Orestis A, et al.
Publicado: (2015)

Cellular Immune Responses 6 Years Following 1, 2, or 3 Doses of Quadrivalent HPV Vaccine in Fijian Girls and Subsequent Responses to a Dose of Bivalent HPV Vaccine
por: Toh, Zheng Quan, et al.
Publicado: (2018)

Potential population-level effectiveness of one-dose HPV vaccination in low-income and middle-income countries: a mathematical modelling analysis
por: Bénard, Élodie, et al.
Publicado: (2023)

Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV‐related disease in females and males
por: Bergman, Hanna, et al.
Publicado: (2019)

Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate
por: Roozendaal, Ramon, et al.
Publicado: (2020)

Methylparaben as a preservative in the development of a multi-dose HPV-2 vaccine
por: Miao, Chenyang, et al.
Publicado: (2022)

HPV vaccination in Kenya: a study protocol to assess stakeholders' perspectives on implementation drivers of HPV vaccination and the acceptability of the reduced dose strategy among providers
por: Umutesi, Grace, et al.
Publicado: (2023)

Decline in HPV-vaccination uptake in Denmark – the association between HPV-related media coverage and HPV-vaccination
por: Suppli, Camilla Hiul, et al.
Publicado: (2018)

Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment
por: Hildesheim, Allan, et al.
Publicado: (2016)

Role of human papillomavirus (HPV) vaccination on HPV infection and recurrence of HPV related disease after local surgical treatment: systematic review and meta-analysis
por: Kechagias, Konstantinos S, et al.
Publicado: (2022)

Examining Provincial HPV Vaccination Schemes in Canada: Should We Standardise the Grade of Vaccination or the Number of Doses?
por: Rogers, Carley, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_sd0gv9p2jtavsgehn9g53m91pd